All Biosimilars Interchangeable? FDA Backs Switching With Spotlight On Science

Latest Review From US Agency Finds ‘Zero Difference’ In Risks When Switching

 
• By David Wallace
  
No Difference - dictionary definition
The FDA found biosimilar switching produced ‘zero difference’ in key risks • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics